90251860 Evaluation of the hypocholesterolemic activity of pautethine in perimenopausal women

Binaghi, P; Cellina, G; Cicero, Giuseppe; Bruschi, F.; Porcaro, E; Penotti, M.

doi:10.1016/0378-5122(91)90104-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro it inhibits fatty acid synthesis and HMG-CoA reductase [ 109 , 110 ]. Several human trials have confirmed these effects in humans [ 111 , 112 ].…”

Section: Inhibitors Of Liver Cholesterol Synthesismentioning

confidence: 99%

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Cicero¹,

Colletti²,

Bajraktari³

et al. 2017

aoms

259

217

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in loss of disability-adjusted life years (DALYs), from a loss of 85 million DALYs in 1990 to a loss of ~150 million DALYs in 2020, becoming a major non-psychological cause of lost productivity [4]. Several risk factors contribute to the etiology and development of CVD; they are divided into those modifiable through lifestyle changes or by taking a pharmacologic treatment (e.g. for hypertension, smoking, diabetes mellitus, hypercholesterolemia) and those that are not modifiable (age, male gender, and family history) [5]. Elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) blood concentrations are the major modifiable risk factors for coronary heart disease (CHD), whereas high concentrations of plasma high-density lipoprotein cholesterol (HDL-C) in certain conditions are considered protective [6]. Moreover, LDL-C remains a fundamental CV risk factor (and a main target of therapy) even when statins are largely used in the general population [7]. An examination of the data of 18 053 participants aged ≥ 20 years who participated in the National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2006 showed that the unadjusted prevalence of hypercholesterolemia ranged from 53.2% to 56.1% in United States adults [8]. Differences related to gender and race or ethnicity were observed; in particular, a lower rate of control was found among women than men and lower rates of having a cholesterol check and being told about hypercholesterolemia were reported by African Americans and Mexican Americans than whites [8]. A recent report from the American Heart Association confirmed that in the US only 75.7% of children and 46.6% of adults present targeted TC levels (TC < 170 mg/dl for children and < 200 mg/dl for adults, in untreated individuals) [9]. The pattern is similar in other Western countries [10, 11]

show abstract

“…In vitro it inhibits fatty acid synthesis and HMG-CoA reductase [ 109 , 110 ]. Several human trials have confirmed these effects in humans [ 111 , 112 ].…”

Section: Inhibitors Of Liver Cholesterol Synthesismentioning

confidence: 99%

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Cicero¹,

Colletti²,

Bajraktari³

et al. 2017

aoms

259

217

View full text Add to dashboard Cite

show abstract

“…In vitro it inhibits fatty acid synthesis and HMG-CoA reductase [109,110]. Several human trials have confirmed these effects in humans [111,112].…”

Section: Pantethinementioning

confidence: 99%

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

et al. 2017

View full text Add to dashboard Cite

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.

show abstract

90251860 Evaluation of the hypocholesterolemic activity of pautethine in perimenopausal women

Cited by 2 publications

References 0 publications

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Contact Info

Product

Resources

About